SCHEMBL7123725

SCHEMBL7123725

Oc1ccc(Nc2ccc(Nc3ncnc4cc(-c5ccccc5)sc34)cc2)cc1

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT1 P17948 10/20 0.85
EGFR P00533 8/20 0.71
FGFR1 P11362 4/20 0.65
KDR P35968 2/20 0.62
ABCG2 Q9UNQ0 1/20 0.52
IKBKB O14920 1/20 0.52
RAF1 P04049 1/20 0.52
BRAF P15056 1/20 0.52
GAA P10253 1/20 0.51
TUBB4A P04350 1/20 0.49
TUBB P07437 1/20 0.49
TUBA3C P0DPH7 1/20 0.49
TUBA1B P68363 1/20 0.49
TUBA4A P68366 1/20 0.49
TUBB4B P68371 1/20 0.49
TUBB3 Q13509 1/20 0.49
TUBB2A Q13885 1/20 0.49
TUBB8 Q3ZCM7 1/20 0.49
TUBA3E Q6PEY2 1/20 0.49
TUBA1A Q71U36 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7126897 0.92 FLT1 (1.00) FLT1EGFRFGFR1KDRIKBKB
SCHEMBL13434839 0.90 FLT1 (0.94) FLT1EGFRFGFR1KDRIKBKB
SCHEMBL7119409 0.88 FLT1 (0.85) FLT1EGFRKDRIKBKBTUBB4A
SCHEMBL7127028 0.88 FLT1 (0.85) FLT1EGFRFGFR1KDRIKBKB
SCHEMBL14777505 0.88 FLT1 (0.77) FLT1EGFRFGFR1KDRIKBKB
SCHEMBL7127078 0.87 FLT1 (0.85) FLT1EGFRFGFR1KDRIKBKB
SCHEMBL7116894 0.86 FLT1 (1.00) FLT1EGFRFGFR1KDRIKBKB
SCHEMBL27521104 0.86 FLT1 (0.83) FLT1EGFRKDRIKBKBTUBB4A
SCHEMBL7123651 0.84 FLT1 (0.84) FLT1EGFRKDRTUBB4ATUBB
SCHEMBL7125076 0.84 EGFR (0.98) FLT1EGFRKDRIKBKBTUBB4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030162795-A1 Thienopyrimidine and thienopyridine derivatives useful as anticancer agents PFIZER INC. 2003-08-28 US claimed
EP-1028964-A1 THIENOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES USEFUL AS ANTICANCER AGENTS Pfizer Products Inc. (US) 2000-08-23 EP claimed
WO-1999024440-A1 THIENOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER PRODUCTS INC. (US) 1999-05-20 WO claimed
US-20030162795-A1 Thienopyrimidine and thienopyridine derivatives useful as anticancer agents PFIZER INC. 2003-08-28 US disclosed
US-6492383-B1 Thienopyrimidine and thienopyridine derivatives useful as anticancer agents PFIZER INC. 2002-12-10 US disclosed
EP-1028964-A1 THIENOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES USEFUL AS ANTICANCER AGENTS Pfizer Products Inc. (US) 2000-08-23 EP disclosed
WO-1999024440-A1 THIENOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER PRODUCTS INC. (US) 1999-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030162795-A1 Thienopyrimidine and thienopyridine derivatives useful as anticancer agents TYMP, DPYD, HPRT1 FLT1 1043/4885EGFR 2961/4885FGFR1 688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.